Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-01

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn whether the profile of RNA from circulating exosomes can be used as a biomarker for lung metastases of primary high-grade osteosarcoma. Circulating exosomes plays roles in metastases in many kinds of cancer including osteosarcoma. By RNA profiling researchers may find lung metastases earlier than conventional work-up and predict the oncological outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma

NCT05101655

Osteosarcoma Pulmonary Metastases

COMPLETED

Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis

NCT03830619

Lung Cancer (Diagnosis)

COMPLETED

Non-small Cell Lung Cancer With Central Nervous System Metastasis

NCT06026735

Lung Cancer With Central Nervous System Metastasis

RECRUITING

CTC in Lung Caner Patients With Bone Metastases

NCT04568291

Lung Cancer Bone Metastases Single Cell Sequencing Technology

UNKNOWN NA

Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer

NCT07262671

NSCLC (Advanced Non-small Cell Lung Cancer)

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators have performed a 4 patients pilot study under the oversight of hospital's ethics committee, and investigator found that the levels and mutations of circulating exosome RNA from patients with or without lung metastasis have significant differences. Then investigators wish to register this study to do a further research, in order to reveal the roles of circulating exosome RNA in metastases of osteosarcoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Metastases Osteosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

metastatic

For osteosarcoma patients with metastasis, collecting blood samples.

Blood samples

Intervention Type OTHER

15 ml peripheral blood

non-metastatic

For osteosarcoma patients without metastasis, collecting blood samples.

Blood samples

Intervention Type OTHER

15 ml peripheral blood

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

15 ml peripheral blood

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis by biopsy: primary high-grade osteosarcoma, including conventional osteosarcoma, telangiectatic osteosarcoma, small cell osteosarcoma, high-grade surface osteosarcoma.
* Tumor located in the extremities or pelvis.
* Age 12-60 years.
* No prior history of cancer and no prior treatment elsewhere.
* No prior history of chronic diseases including autoimmune disease, chronic infection, etc. which may interfere the level of circulating exosomes.

Exclusion Criteria

* Initial misdiagnosis confirmed by specimen of definitive surgery.
* Applying target drugs in the period of treatment which may reduce tumor derived exosomes
* withdraw from the study for any reason

Minimum Eligible Age

12 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No